Artigo de periodico

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation (2019)

• Authors:
  • Fruchart, Jean-Charles
  • Santos Filho, Raul Dias dos
  • Aguilar-salinas, Carlos
  • Aikawa, Masanori
  • Rasadi, Khalid Al
  • Amarenco, Pierre
  • Barter, Philip J
  • Ceska, Richard
  • Corsini, Alberto
  • Despres, Jean-Pierre
• Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
• Unidade: FM
• DOI: 10.1186/s12933-019-0864-7
• Subjects: DOENÇAS CARDIOVASCULARES; ARTERIOSCLEROSE; DISLIPIDEMIAS; LIPÍDEOS; LIPOPROTEÍNAS HDL; DIABETES MELLITUS NÃO INSULINO-DEPENDENTE; PEROXISSOMOS
• Agências de fomento:
  • R3i
• Language: Inglês
• Imprenta:
  • Publisher place: London
  • Date published: 2019
• Source:
  • Título do periódico: Cardiovascular diabetology
  • ISSN: 1475-2840
  • Volume/Número/Paginação/Ano: v. 18, article ID 71, 20p, 2019

Informações sobre o DOI: 10.1186/s12933-019-0864-7 (Fonte: oaDOI API)
• Este periódico é de acesso aberto
• Este artigo é de acesso aberto
• URL de acesso aberto
• Cor do Acesso Aberto: gold
• Licença: cc-by

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  FRUCHART, Jean-Charles et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovascular diabetology, v. 18, 2019Tradução . . Disponível em: https://doi.org/10.1186/s12933-019-0864-7. Acesso em: 07 jun. 2024.

• APA

  Fruchart, J. -C., Santos Filho, R. D. dos, Aguilar-salinas, C., Aikawa, M., Rasadi, K. A., Amarenco, P., et al. (2019). The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovascular diabetology, 18. doi:10.1186/s12933-019-0864-7

• NLM

  Fruchart J-C, Santos Filho RD dos, Aguilar-salinas C, Aikawa M, Rasadi KA, Amarenco P, Barter PJ, Ceska R, Corsini A, Despres J-P. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation [Internet]. Cardiovascular diabetology. 2019 ; 18[citado 2024 jun. 07 ] Available from: https://doi.org/10.1186/s12933-019-0864-7

• Vancouver

  Fruchart J-C, Santos Filho RD dos, Aguilar-salinas C, Aikawa M, Rasadi KA, Amarenco P, Barter PJ, Ceska R, Corsini A, Despres J-P. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation [Internet]. Cardiovascular diabetology. 2019 ; 18[citado 2024 jun. 07 ] Available from: https://doi.org/10.1186/s12933-019-0864-7

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Foi com muita satisfação que recebemos o convite dos ...[Apresentação]
• Relation of Uric Acid to Serum Levels of High-Sensitivity C-Reactive Protein, Triglycerides, and High-Density Lipoprotein Cholesterol and to Hepatic Steatosis
• Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
• Elevated uric acid, the metabolic syndrome and cardiovascular disease [Editorial]: cause, consequence, or just a not so innocent bystander?
• Lipid-lowering treatment for homozygous familial hypercholesterolaemia [Carta]
• Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease
• A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?
• Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
• Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
• Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome